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a b s t r a c t
A 49-year-old Caucasian woman presented to the dermatology clinic for follow-up of malignant mela-
noma with a complaint of painless gross hematuria. Two years prior she was diagnosed with malignant
melanoma from a skin lesion on her left flank treated with wide excision, negative axillary sentinel
lymph node biopsy, and adjuvant radiotherapy. Subsequently, she had no evidence of disease until
urologic evaluation of her hematuria revealed two lesions in her bladder and cytopathology demon-
strated findings consistent with malignant melanoma. We review literature on melanoma metastatic to
the bladder and discuss the potential role of metastasectomy and other treatment strategies in such rare
cases.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
While melanoma represents the deadliest form of skin cancer,
reported cases of metastasis to the bladder are rare, with just 29
confirmed cases reported in English-language literature. This
number is likely an underestimation of the true burden of disease,
as autopsy series of patients with metastatic melanoma have found
an 18%e37% rate of metastatic disease to the bladder.1,2 Nonethe-
less, metastatic disease that presents in the bladder is rare and
poses a significant challenge in diagnosis and management. We
report a case that highlights such challenges and review literature
on metastatic melanoma with a focus on bladder metastases.
Case presentation
A 49-year-old Caucasian woman presented to the dermatology
clinic for follow-up of her malignant melanoma with a complaint
of painless gross hematuria. Two years prior she was diagnosed
with malignant melanoma from a skin lesion on her left flank. She
had a wide excision with negative margins and a negative axillary
sentinel lymph node biopsy. The pathology confirmed stage IIC
(7 mm thickness, Clark level IV) malignant melanoma and she
received 3000 cGy of adjuvant radiotherapy to the left flank. The
patient had no evidence of disease until her presentation with
hematuria. A computed tomography (CT) scan demonstrated two
enhancing lesions in the bladder, with the largest one measuring
33 mm in largest diameter along the left posterolateral bladder
wall (Fig. 1A). Voided urine cytology identified cells that expressed
S-100, HMB-45, and Melan-A, consistent with malignant mela-
noma (Fig. 2). Cystoscopy demonstrated a large nodular mass with
brown pigmentation on the left trigone as well as multiple
discontinuous nodular lesions on the left lateral wall (Fig. 1B).
Although the remainder of her abdominal/pelvic CT was free of
visible disease, a more thorough metastatic survey was
completed, and brain magnetic resonance imaging demonstrated
frontal and occipital lobe lesions consistent with metastatic dis-
ease. Given the multiple sites of metastatic disease, we felt the
patient was not likely to derive a survival benefit from meta-
stasectomy, which for complete resection in the location of her
trigone would likely require cystectomy. She was treated conser-
vatively with stereotactic body radiation therapy (SBRT) of the
brain metastases, systemic therapy with checkpoint inhibitor
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging;
TURBT, transurethral resection of bladder tumor; TUR, transurethral resection;
SBRT, stereotactic body radiation therapy.
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combination therapy of nivolumab and ipilimumab, and cysto-
scopic intervention planned for episodes of intractable hematuria.
Discussion
Malignant melanoma is the deadliest skin cancer in the United
States with over 67,000 new cases per year and an estimated 30%
will eventually develop metastases.3 While the majority of meta-
static spread occurs to skin, lungs, liver, and brain, metastasis to the
bladder in clinical series appear to be rare with only 29 reported
cases in the literature (Table 1). This in contrast to autopsy series
which indicate an 18%e37% incidence of metastatic disease in the
bladder.1,2 The most common presenting symptom is hematuria,
and isolated metastatic disease to the bladder is relatively rare. The
confirmation of metastatic melanoma is made possible through
immunohistochemical analysis demonstrating characteristic
expression of S-100, HMB-45, MART-1/Melan-A, tyrosinase, and
MITF.
Once metastatic, treatment options are limited and survival is
generally poor, reflecting a lack of effective systemic therapies.
Chemotherapeutics have limited effect on survival, however the
introduction of immunotherapy has been promising in select cases.
Interleukin-2 therapy was introduced in the late 1990s but with a
low response rate and significant side effects including an inflam-
matory response syndrome that often limits treatment. Targeted
therapies in the form of BRAF, MEK, KIT, VEGF pathway inhibitors
have improved response rates, but not durably. More recent use of
checkpoint inhibitors including antibodies targeting PD-1 or PD-L1
and CTLA4 are promising due to higher response rates and a chance
of durable response.4
Location of the initial metastatic site appears to be a signifi-
cant predictor of survival with improved survival for skin me-
tastases, and progressively lower survival associated with distant
nodal involvement, gastrointestinal, lung, bone, liver, and brain
metastasis. Given the few cases of bladder metastases reported in
the literature, it is not clear if this location portends a worse
outcome.
The question for urologists dealingwithmetastatic melanoma to
the bladder is: does surgery play a role in the management, and if
so, should management be transurethral resection (TUR) or cys-
tectomy? Similar to genitourinary malignancies, metastasectomy
for malignant melanoma is controversial, but retrospective data
suggests metastasectomy may be associated with improved overall
survival compared to systemic therapy alone.5 The role of meta-
stasectomy in the era of newer effective systemic agents is likely to
be answered in future studies, but at present, a multidisciplinary
team of surgeons, radiation oncologists, and medical oncologists
should jointly devise a treatment strategy. In the other reported
cases of metastatic melanoma to the bladder, treatment varied from
observation, transurethral resection, and even cystectomy. The
choice of surgical strategy should be based on overall prognosis, the
patient’s health status, presence of local symptoms attributable to
bladder metastases, invasiveness of approach, and quality of life
factors. Bladder metastases resulting in hematuria and voiding
symptoms that can sometimes be managed by TUR, however TUR
may not be sufficient to remove the entire tumor in many cases.
Obviously, radical cystectomy or partial cystectomy for metastatic
disease represents a markedly aggressive step compared to TUR,
and such cases should probably be limited to those with solitary or
limited metastatic disease and favorable prognostic factors. Unfor-
tunately, our patient had concomitant brain metastasis and we felt
Figure 1. Panel A. Axial section CT abdomen/pelvis with IV and oral contrast demonstrating a left posterolateral bladder wall-enhancing lesion measuring 33 mm in largest
diameter. Panel B. Cystoscopy reveals large nodular mass (w3 cm) with brown pigmentation at left posterolateral wall of bladder as well as satellite lesions.
Figure 2. Cytologic assessment of voided urine demonstrating malignant melanoma diagnosis. Panel A. Malignant cells with fine, brown melanin pigment (H&E stain, 400). Panel
B. Immunohistochemical stain positive for HMB-45 (red chromogen, 400). Panel C. Immunohistochemical stain positive for S-100 (brown chromogen, 400).
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there was limited evidence she would benefit from more invasive
surgery. We elected to administer SBRT for her brain lesions, offer
systemic therapy with combined checkpoint inhibitor immuno-
therapy, and manage her bladder metastasis conservatively.
Growing evidence suggests the efficacy of SBRT in melanoma,
despite previous consideration that this tumor was ‘radioresistant,’
and possible synergistic effects of radiation with immunotherapy,
the so-called ‘abscopal effect.’
Table 1
Review of English-language literature of metastatic melanoma to the bladder.





Amar, Journal of Urology (1964),
14213534
33yo Male Hematuria Maxillary lesions Partial cystectomy NR
Bartone, Journal of Urology, (1964),
14118110
70yo Female Hematuria Lymph nodes Partial cystectomy Died within 2 months
Weston and Smith, British Journal
of Surgery, (1964), 14103391
69yo Male Urinary retention Widespread None Died 5 days after diagnosis
Dasgupta and Grabstald, Journal












A. Died within 4 months
B. NR














B. Died 16 months after
resection
C. Died 2 months after
resection
Silverstein et al, JAMA (1974), 4408302 56yo Male Hematuria Lymph nodes Intratumor injection of
BCG vaccine followed by
partial cystectomy
Alive at 8 month
follow-up
Tolley et al, British Journal of
Clinical Practice (1975), 1191491
48yo Female Hematuria Absent Radical cystectomy NR
Chin et al, Journal of Urology (1982),
7062434






Stein and Kendall, Journal of
Urology (1984), 6387180
50yo Male Hematuria Absent TUR chemotherapy Alive at 2 year follow-up
Arapantoni-Dadioti et al, European
Journal of Surgical Oncology (1995),
7851567
28yo Female Dysuria Brain
Lungs
Lymph nodes
Incomplete TUR 2 months after resection
Ergen at al, International






Biopsy Died within 1 week
Demiksesen et al, Urologia
Internationalis (2000), 10810279
45yo Female Hematuria, urinary
frequency
Widespread TUR chemotherapy NR





49yo Male Hematuria NR NR NR
Efesoy and Cayan, Medical
Oncology (2011), 21042956
60yo Female Hematuria weight loss Lungs TUR Died 7 months after
resection
Nair et al, Journal of Clinical Oncology
(2011), 21189399
54yo Male Hematuria Widespread including
ureteral and
renal pelvic tumors
TUR and laser ablation
of ureteral and renal
pelvic tumors
Chemotherapy
Died within 3 months
of TURBT
Charfi et al, Case Reports Pathology (2012),
23133774
54yo Male Unknown Lymph nodes TUR Died within 1 month
Paterson et al, Central European Journal of
Urology (2012), 24578971
84yo Male Incidental No other metastatic
lesions
None NR





















A. Alive at 10 months
B. Died at 4 months
C. Died within 4 months
D. Died within 5 months
Rishi et al, International Journal of










Died with 2 months
Meunier et al, Case Reports
Pathology (2015), 26106499




Shukla et al, Journal Endourology
Case Reports (2016), 27579421
60yo Male Hematuria Widespread TUR Alive at 1 year follow-up
Current report 49yo Female Hematuria Brain Brain SBRT, checkpoint
inhibitors
-
TURetransurethral resection; SBRTestereotactic body radiotherapy; NRenot reported.
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Conclusion
Reported cases of metastatic melanoma to the bladder are rare.
While long-term survival of patients with metastatic melanoma is
rare, evolving treatment strategies and increasing acceptance of a
survival benefit to metastasectomy in certain settings poses signifi-
cant challenges to management. Integrating urologic treatments into
a multidisciplinary strategy is important in managing these patients.
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